Home Healthcare Biotechnology Antisense Oligonucleotides Market

Antisense Oligonucleotides Market Size, Share & Trends Analysis Report By Drug Chemistry (Phosphorothioate-modified ASOs, 2'O-methoxyethyl (2'-MOE) ASOs, Locked-Nucleic-Acid (LNA) gapmers, Constrained Ethyl (cEt) ASOs, PMO Morpholino ASOs, Peptide Nucleic Acid (PNA) ASOs), By Therapeutic Area (Neurological & Neuromuscular Disorders, Oncology, Cardiometabolic & Renal Disorders, Ophthalmology, Infectious Diseases, Metabolic & Endocrine Disorders, Auto-immune Disorders), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Hospitals & Specialised Clinics, CROs & CMOs) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: October 16, 2026 | Author: Debashree Bora | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Antisense Oligonucleotides Market, By Drug Chemistry 2025-2034 (USD MILLION/ Units)
    1. Phosphorothioate-modified ASOs
    2. 2'O-methoxyethyl (2'-MOE) ASOs
    3. Locked-Nucleic-Acid (LNA) gapmers
    4. Constrained Ethyl (cEt) ASOs
    5. PMO Morpholino ASOs
    6. Peptide Nucleic Acid (PNA) ASOs
  2. Antisense Oligonucleotides Market, By Therapeutic Area 2025-2034 (USD MILLION/ Units)
    1. Neurological & Neuromuscular Disorders
    2. Oncology
    3. Cardiometabolic & Renal Disorders
    4. Ophthalmology
    5. Infectious Diseases
    6. Metabolic & Endocrine Disorders
    7. Auto-immune Disorders
  3. Antisense Oligonucleotides Market, By End User 2025-2034 (USD MILLION/ Units)
    1. Pharmaceutical & Biotechnology Companies
    2. Academic & Research Institutes
    3. Hospitals & Specialised Clinics
    4. CROs & CMOs
  4. Regional Antisense Oligonucleotides Market
    1. North America
      1. North America Antisense Oligonucleotides Market By Drug Chemistry 2025-2034 (USD MILLION/ Units)
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
      2. North America Antisense Oligonucleotides Market By Therapeutic Area 2025-2034 (USD MILLION/ Units)
        1. Neurological & Neuromuscular Disorders
        2. Oncology
        3. Cardiometabolic & Renal Disorders
        4. Ophthalmology
        5. Infectious Diseases
        6. Metabolic & Endocrine Disorders
        7. Auto-immune Disorders
      3. North America Antisense Oligonucleotides Market By End User 2025-2034 (USD MILLION/ Units)
        1. Pharmaceutical & Biotechnology Companies
        2. Academic & Research Institutes
        3. Hospitals & Specialised Clinics
        4. CROs & CMOs
      4. U.S.
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
      5. Canada
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
    2. Europe
      1. Europe Antisense Oligonucleotides Market By Drug Chemistry 2025-2034 (USD MILLION/ Units)
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
      2. Europe Antisense Oligonucleotides Market By Therapeutic Area 2025-2034 (USD MILLION/ Units)
        1. Neurological & Neuromuscular Disorders
        2. Oncology
        3. Cardiometabolic & Renal Disorders
        4. Ophthalmology
        5. Infectious Diseases
        6. Metabolic & Endocrine Disorders
        7. Auto-immune Disorders
      3. Europe Antisense Oligonucleotides Market By End User 2025-2034 (USD MILLION/ Units)
        1. Pharmaceutical & Biotechnology Companies
        2. Academic & Research Institutes
        3. Hospitals & Specialised Clinics
        4. CROs & CMOs
      4. U.K.
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
      5. Germany
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
      6. France
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
      7. Spain
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
      8. Italy
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
      9. Russia
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
      10. Nordic
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
      11. Benelux
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
      12. Rest of Europe
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
    3. APAC
      1. APAC Antisense Oligonucleotides Market By Drug Chemistry 2025-2034 (USD MILLION/ Units)
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
      2. APAC Antisense Oligonucleotides Market By Therapeutic Area 2025-2034 (USD MILLION/ Units)
        1. Neurological & Neuromuscular Disorders
        2. Oncology
        3. Cardiometabolic & Renal Disorders
        4. Ophthalmology
        5. Infectious Diseases
        6. Metabolic & Endocrine Disorders
        7. Auto-immune Disorders
      3. APAC Antisense Oligonucleotides Market By End User 2025-2034 (USD MILLION/ Units)
        1. Pharmaceutical & Biotechnology Companies
        2. Academic & Research Institutes
        3. Hospitals & Specialised Clinics
        4. CROs & CMOs
      4. China
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
      5. Korea
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
      6. Japan
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
      7. India
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
      8. Australia
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
      9. Taiwan
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
      10. South East Asia
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
      11. Rest of Asia-Pacific
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
    4. Middle East and Africa
      1. Middle East and Africa Antisense Oligonucleotides Market By Drug Chemistry 2025-2034 (USD MILLION/ Units)
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
      2. Middle East and Africa Antisense Oligonucleotides Market By Therapeutic Area 2025-2034 (USD MILLION/ Units)
        1. Neurological & Neuromuscular Disorders
        2. Oncology
        3. Cardiometabolic & Renal Disorders
        4. Ophthalmology
        5. Infectious Diseases
        6. Metabolic & Endocrine Disorders
        7. Auto-immune Disorders
      3. Middle East and Africa Antisense Oligonucleotides Market By End User 2025-2034 (USD MILLION/ Units)
        1. Pharmaceutical & Biotechnology Companies
        2. Academic & Research Institutes
        3. Hospitals & Specialised Clinics
        4. CROs & CMOs
      4. UAE
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
      5. Turkey
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
      6. Saudi Arabia
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
      7. South Africa
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
      8. Egypt
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
      9. Nigeria
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
      10. Rest of MEA
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
    5. LATAM
      1. LATAM Antisense Oligonucleotides Market By Drug Chemistry 2025-2034 (USD MILLION/ Units)
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
      2. LATAM Antisense Oligonucleotides Market By Therapeutic Area 2025-2034 (USD MILLION/ Units)
        1. Neurological & Neuromuscular Disorders
        2. Oncology
        3. Cardiometabolic & Renal Disorders
        4. Ophthalmology
        5. Infectious Diseases
        6. Metabolic & Endocrine Disorders
        7. Auto-immune Disorders
      3. LATAM Antisense Oligonucleotides Market By End User 2025-2034 (USD MILLION/ Units)
        1. Pharmaceutical & Biotechnology Companies
        2. Academic & Research Institutes
        3. Hospitals & Specialised Clinics
        4. CROs & CMOs
      4. Brazil
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
      5. Mexico
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
      6. Argentina
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
      7. Chile
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
      8. Colombia
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
      9. Rest of LATAM
        1. Phosphorothioate-modified ASOs
        2. 2'O-methoxyethyl (2'-MOE) ASOs
        3. Locked-Nucleic-Acid (LNA) gapmers
        4. Constrained Ethyl (cEt) ASOs
        5. PMO Morpholino ASOs
        6. Peptide Nucleic Acid (PNA) ASOs
        7. Neurological & Neuromuscular Disorders
        8. Oncology
        9. Cardiometabolic & Renal Disorders
        10. Ophthalmology
        11. Infectious Diseases
        12. Metabolic & Endocrine Disorders
        13. Auto-immune Disorders
        14. Pharmaceutical & Biotechnology Companies
        15. Academic & Research Institutes
        16. Hospitals & Specialised Clinics
        17. CROs & CMOs
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.